Chagas disease and SARS-CoV-2 coinfection does not lead to worse in-hospital outcomes

Posted: 2021-10-14 19:00:00
Chagas disease (CD) continues to be a major public health burden in Latina America. Information on the interplay between COVID-19 and CD is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients. Consecutive patients with confirmed COVID-19 were included from March to September 2020. Genetic matching for sex, age, hypertension, diabetes mellitus and hospital was performed in a 4:1 ratio. Of the 7018 patients who had confirmed COVID-19, 31 patients with CD and 124 matched controls were included (median age 72 (64-80) years-old, 44.5% were male). At baseline, heart failure (25.8% vs. 9.7%) and atrial fibrillation (29.0% vs. 5.6%) were more frequent in CD patients than in the controls (p < 0.05). C-reactive protein levels were lower in CD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). In-hospital management, outcomes and complications were similar between the groups. In this large Brazilian COVID-19 Registry, CD patients had a higher prevalence of atrial fibrillation and chronic heart failure compared with non-CD controls, with no differences in-hospital outcomes. The lower C-reactive protein levels in CD patients require further investigation.

参考サイト PubMed: covid-19


2月 10, 2021 バイオアソシエイツ


シカゴにあるラッシュ大学医療センターの新研究で、マウスの COVID-19 モデルに鼻からペプチドを導入したところ、効果を示したという。 このペプチドは、発熱を抑え、肺を保護し、心臓機能を改善し、「サイトカインストーム」(感染が免疫系を誘発して炎症性タンパク質で血流を溢れさせる状態)を逆転させるのに効果的であることが証明された。この研究者らはまた、病気の進行を防ぐことに成功したと報告している。2021年1月11日にJournal of Neuroimmune…

ゲスト 707人 と メンバー 6人 がオンラインです